Company intelligence / Profile preview
IMMIOS
Not specified, Not specified, Netherlandsimmios-biotech.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
IMMIOS is a newly established biotechnology company focused on developing new medicines at the intersection of immunology and oncology. The company aims to translate cutting-edge science into innovative therapeutics for autoimmune diseases and cancer. No clinical results have been published yet as they appear to be in an early stage
- Therapeutic areas
- OncologyImmunology
- Modalities
- Not explicitly stated; likely includes biologics or novel therapeutics at the interface of immunology and oncology
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on IMMIOS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMMIOS.